drugset / Trial / NCT01573598

Safety and Efficacy of Vilazodone in Major Depressive Disorder

NCT01573598

Phase 4 Completed 1219 enrolled Forest Laboratories
RandomizedParallel-groupTriple-blindTreatment

Summary

Safety and Efficacy of Vilazodone in Major Depressive Disorder

Timeline

Start
2012-04
Primary completion
2014-10
Completion
2015-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Vilazodone Small molecule 20 mg Oral
Subject Vilazodone Small molecule 40 mg Oral